Latest Information Update: 27 Apr 2000
At a glance
- Originator Zenyth Therapeutics
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 27 Apr 2000 Discontinued-Preclinical for Pain in Australia (Unknown route)
- 14 Feb 2000 Preclinical development for Pain in Australia (Unknown route)